Last reviewed · How we verify
GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
GlaxoSmithKline Biologicals' influenza vaccine GSK576389A is a Influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Prevention of influenza caused by virus subtypes A and B.
Induces an immune response against influenza viruses through the presentation of viral antigens to the immune system.
Induces an immune response against influenza viruses through the presentation of viral antigens to the immune system. Used for Prevention of influenza caused by virus subtypes A and B.
At a glance
| Generic name | GlaxoSmithKline Biologicals' influenza vaccine GSK576389A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Influenza vaccine |
| Target | Influenza virus antigens |
| Modality | Biologic |
| Therapeutic area | Vaccines |
| Phase | Phase 2 |
Mechanism of action
The vaccine contains inactivated influenza virus strains that stimulate the production of antibodies against the virus, thereby providing protection against influenza infection.
Approved indications
- Prevention of influenza caused by virus subtypes A and B
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
- Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over (PHASE2)
- Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations (PHASE2)
- Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A (PHASE2)
- Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE2)
- Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GlaxoSmithKline Biologicals' influenza vaccine GSK576389A CI brief — competitive landscape report
- GlaxoSmithKline Biologicals' influenza vaccine GSK576389A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
What is GlaxoSmithKline Biologicals' influenza vaccine GSK576389A?
How does GlaxoSmithKline Biologicals' influenza vaccine GSK576389A work?
What is GlaxoSmithKline Biologicals' influenza vaccine GSK576389A used for?
Who makes GlaxoSmithKline Biologicals' influenza vaccine GSK576389A?
What drug class is GlaxoSmithKline Biologicals' influenza vaccine GSK576389A in?
What development phase is GlaxoSmithKline Biologicals' influenza vaccine GSK576389A in?
What are the side effects of GlaxoSmithKline Biologicals' influenza vaccine GSK576389A?
What does GlaxoSmithKline Biologicals' influenza vaccine GSK576389A target?
Related
- Drug class: All Influenza vaccine drugs
- Target: All drugs targeting Influenza virus antigens
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Vaccines
- Indication: Drugs for Prevention of influenza caused by virus subtypes A and B
- Compare: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A vs similar drugs
- Pricing: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A cost, discount & access